The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.
 
Peter Galle
Honoraria - Adaptimmune; AstraZeneca/MedImmune; Bayer Schering Pharma; Bristol-Myers Squibb; Ipsen; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - AstraZeneca; Bayer Schering Pharma; BMS GmbH & Co. KG; Ipsen; Lilly; Roche
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Bayer Schering Pharma; Lilly; Roche/Genentech; Sirtex Medical
 
Jordi Bruix
Consulting or Advisory Role - Basilea; BMS GmbH & Co. KG; Roche; Terumo; Universal Diagnostics
Speakers' Bureau - Roche Pharma AG
Travel, Accommodations, Expenses - AstraZeneca; Roche Pharma AG
 
Roman Kloeckner
No Relationships to Disclose
 
Joerg Trojan
No Relationships to Disclose
 
Thomas Vogl
No Relationships to Disclose
 
Tom Ludde
No Relationships to Disclose
 
Pietro Lampertico
No Relationships to Disclose
 
Jean-Charles Nault
No Relationships to Disclose
 
Mohamed Bouattour
No Relationships to Disclose
 
Thorsten Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly; MSD Oncology
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)
 
Philippe Merle
Honoraria - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; EISAI; Ipsen; Lilly; Merck; Roche
Consulting or Advisory Role - Bayer Schering Pharma
 
Anna Saborowski
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; MSD; Roche; Servier
Consulting or Advisory Role - BMS; Eisai; Incyte; MSD; Roche/Genentech
Travel, Accommodations, Expenses - Eisai; MSD; Pierre Fabre; SERVIER
 
Markus Peck-Radosavljevic
Consulting or Advisory Role - AstraZeneca; BMS GmbH & Co. KG; Eisai Europe; Ipsen; Roche
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Vikas Ostwal
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BDR Pharmaceutics (Inst); Cadila Pharmaceuticals (Inst); Dr. Reddy's Laboratories (Inst); Intas (Inst); Lupin Pharmaceuticals (Inst); Merck (Inst); MSD (Inst); NATCO Pharma (Inst); Panacea Pharmaceuticals (Inst); Panacea Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Intas; Merck; NATCO Pharma; NATCO Pharma; PredOmix Technologies Pvt
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Matthias Pinter
No Relationships to Disclose
 
Alessandra Auriemma
No Relationships to Disclose
 
Masatoshi Kudo
Honoraria - AstraZeneca; Chugai/Roche; Eisai
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai
Research Funding - Eisai (Inst); GE Healthcare (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Maria Reig
Consulting or Advisory Role - AstraZeneca; Bayer; BMS GmbH & Co. KG; BMS GmbH & Co. KG; Boston Scientific; Engitix; Geneos; Ipsen; Lilly; Merck; Parabilis Medicines; Roche; Universal Diagnostics
Speakers' Bureau - AstraZeneca; Bayer; Bayer; Biotoscana Farma; BMS GmbH & Co. KG; Gilead Sciences; Lilly; Roche
Research Funding - Bayer (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS GmbH & Co. KG; Ipsen; Lilly; Roche
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Frankfurter Institut für Klinische Krebsforschung IKF GmbH
Consulting or Advisory Role - Bristol-Myers Squibb; Eli Lilly Germany; Merck Sharp & Dohme
Speakers' Bureau - MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Immutep; Ipsen; Lilly; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma
 
Friedrich Foerster
Honoraria - AstraZeneca; BMS GmbH & Co. KG; Roche; SERVIER; Taiho Oncology
Consulting or Advisory Role - BlueJay Therapeutics
Speakers' Bureau - AstraZeneca; Lilly; Merck; Takeda
Travel, Accommodations, Expenses - BeOne Medicines; SERVIER